Announcement under Reg 30 SEBI(LODR)- Investor Presentation
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hikal Ltd reported Q4 FY26 revenue of Rs. 519 Cr with EBITDA margin of 20.3%, a significant improvement from Q3's 16.8%. For full year FY26, revenue stood at Rs. 1,713 Cr with EBITDA margin of 12.9% (vs 17.7% in FY25), impacted by exceptional items of Rs. 85 Cr including labor code adjustment and asset impairment. Pharmaceuticals segment posted Rs. 692 Cr revenue with EBIT of Rs. 51 Cr, recovering from H1 regulatory headwinds. Crop Protection showed recovery with Rs. 1,021 Cr revenue and EBIT of Rs. 33 Cr, though pricing remains competitive due to overcapacity. The company highlighted new strategic investments (HPAPI lab, Pune kilo lab, Panoli pilot plant) now fully operational. Management emphasized moving from remediation phase to sustainable growth, with focus on improving product mix and expanding CDMO pipeline.
Strong Q4 margin recovery to 20.3% signals operational improvements are translating into financials. Full year margin compression to 12.9% reflects earlier challenges, but management's focus on higher-value CDMO work and new product commercialization from FY27 onwards could drive margin expansion going forward.